A Scalable Platform with Structural Advantage
Unlike genomics-only approaches, which predict response based on mutation patterns, fScreen directly measures drug efficacy in real patient cells. Built on standardized high-throughput flow cytometry and integrated analytics software, fResolve, the platform is engineered to enable:
Transforming Cancer Treatment with Functional Precision
exalt® is building the next generation of precision oncology—moving beyond genomic probability toward direct, functional measurement of treatment response.
Our proprietary platform, fScreen, is testing how a patient’s living tumor cells respond to more than 100 approved cancer drugs at single-cell resolution. Within 72 hours, oncologists will receive a ranked, actionable treatment profile—enabling evidence-based therapy selection tailored to the individual patient.
In clinical studies, fScreen-guided therapy has demonstrated significantly improved response rates in late-stage hematologic cancers, validating the power of functional precision medicine.
The right Drug.
For the right Patient.
At the right Time.
Our Vision
exalt® aims to make functional precision diagnostics the global standard of care—reducing ineffective treatments, improving patient outcomes, and unlocking a new data-driven era of oncology.
News
15 February 2024
Nature biotechnology
Staber and his team are now recruiting patients into a second prospective study in patients with hematological cancer, EXALT-2, which is comparing the utility of genomic screening, single-cell functional precision medicine and physicians’ choice in guiding therapy selection.
23 November 2023
Pre-Seed AWS Deeptech
exalt receives support by the Austrian Promotional Bank Deep Tech Pre-Seed.
Clinical trials
Publications
EXALT-2 Clinical Trial - feasibility analysis
Comparing functional and genomic-based precision medicine in blood cancer patients
Hemasphere 24 April 2025
Lukas Kazianka, Alexander Pichler, ..., Tea Pemovska et Philipp Staber
EXALT-1 Clinical Trial
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Cancer Discovery
1 February 2022
Christoph Kornauth, Tea Pemovska, Gregory I. Vladimer, ..., Giulio Superti-Furga; Berend Snijder et Philipp B. Staber
Team
Tea Pemovska, PhD
CSO
co-founder
Gabriela Staber, Dr. iur LLM
Legal
co-founder
Alexander Pichler, MD
CEO
co-founder
